Table 1 Demographic characteristics of study groups and summary data of serum SARS-CoV-2 neutralizing antibody levels.
vaccine (manufacturer) | NVX-CoV2373 (Novavax) | Comirnaty (Pfizer-BioNTech) | Vaxzevria (AstraZeneca) |
|---|---|---|---|
n | 30 | 35 | 12 |
mean donor age (min−max) [yr] | 53 (20–76) | 39 (23–62) | 44 (27–59) |
female | 43% | 66% | 75% |
male | 57% | 34% | 25% |
ethnicity | Asian | White | White |
mean time since 1st vaccination ± SD [d] | 36 ± 0 | 49 ± 4 | 106 ± 3 |
mean time since 2nd vaccination ± SD [d] | 15 ± 0 | 27 ± 3 | 26 ± 4 |
geometric mean (lower; upper 95% CI) of anti-SARS-CoV-2 potency [IU/ml] | 548 (368; 818) | 557 (428; 725) | 202 (107; 382) |
